You are here
Pearl River, NY
Location: Orangetown and Clarkstown, Rockland County, NY
Pfizer Worldwide Research and Development areas of focus:
Manufacturing Capabilities: Antibody Drug Conjugates
In-market products supported:
- Prevnar 13
Total acreage owned by Pfizer: approximately 330 acres
Developed land: approximately 22.9 acres
Number of buildings: 4
Number of colleagues: more than 800
Pearl River is one of Pfizer’s nine major R&D sites.
Vaccine Research and Development in Pearl River develops first-in-class and best-in-class vaccines against diseases of major public health importance that impact all ages and geographies. Pearl River colleagues have developed and manufactured vaccines for more than a century. Today, Vaccine Research & Development is a fully integrated organization with responsibilities from the early-idea stage through clinical development, product registration and post-marketing commitments.
Major recent accomplishments include leading the research and development efforts that resulted in the licensure of Prevnar-13® and Trumenba. The development of Prevnar-13® earned Pfizer scientists the Prix Galien USA award in 2011. More advanced formulations of Prevnar to combat additional strains of pneumococcal disease are a major focus of Pearl River’s current research efforts. Pneumococcal disease is a leading cause of vaccine-preventable death worldwide in children younger than five years. It encompasses a complex group of illnesses, including bacteremia/sepsis and meningitis.
Pearl River scientists are currently working to develop vaccines against other major infectious disease targets such as Clostridium difficile. This pathogen is described as an “urgent threat” by the Centers for Disease Control. Scientists are also developing maternal vaccines to protect against Group B streptococcus and respiratory syncytial virus (RSV) - dangerous pathogens that cause serious infections in newborns.
The Pearl River-Oncology Research Unit is focused on creating targeted therapies against a broad spectrum of cancers. The group has developed novel targeted therapies, including antibody drug conjugates (ADCs), bispecific antibodies, immunotherapies and nanoparticles targeting tumor, immune and stromal cells.
Further, the Pearl River-Oncology Research Unit has deep expertise in functional genomics, chemogenomics and proteomics and is using these approaches to identify novel first in class cancer targets and therapies to combine with existing Oncology assets and for modulation of the anti-cancer immune system.
The Pearl River site has a rich history spanning over 100 years of advancing science, fighting disease and delivering products that promote global health. A number of innovations have been developed in Pearl River. These medical products include Torisel®, a treatment for patients with advanced renal cell carcinoma. Centrum®, the world’s top-selling multivitamin, was also developed and first manufactured in Pearl River.